BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1183 related articles for article (PubMed ID: 29139555)

  • 1. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
    Wang W; Zhao J; Gui W; Sun D; Dai H; Xiao L; Chu H; Du F; Zhu Q; Schnabl B; Huang K; Yang L; Hou X
    Br J Pharmacol; 2018 Feb; 175(3):469-484. PubMed ID: 29139555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P; Wang J; Li D; Ke W; Chen F; Hu X
    J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of Ilexhainanoside D and ilexsaponin A
    Zhao W; Xiao M; Yang J; Zhang L; Ba Y; Xu R; Liu Z; Zou H; Yu P; Wu X; Chen X
    Phytomedicine; 2019 Oct; 63():153039. PubMed ID: 31387054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis.
    Lan T; Xu T; Fu Y; Jiang S; Liang X; Yu Z; Pan L; Rong X; Guo J
    Front Endocrinol (Lausanne); 2022; 13():864703. PubMed ID: 35784533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
    Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
    Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse.
    Lee JE; Lee SM; Jung J
    Phytomedicine; 2020 Dec; 79():153354. PubMed ID: 32992082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
    Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
    J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.
    Zhou D; Pan Q; Xin FZ; Zhang RN; He CX; Chen GY; Liu C; Chen YW; Fan JG
    World J Gastroenterol; 2017 Jan; 23(1):60-75. PubMed ID: 28104981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Tauroursodeoxycholic acid (TUDCA) and gut microbiota on murine gallbladder stone formation.
    Lu Q; Jiang Z; Wang Q; Hu H; Zhao G
    Ann Hepatol; 2021; 23():100289. PubMed ID: 33217585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway.
    Leng J; Huang F; Hai Y; Tian H; Liu W; Fang Y; Hu Y; Peng J
    Phytomedicine; 2020 Jan; 66():153135. PubMed ID: 31790895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tauroursodeoxycholic Acid Reverses Dextran Sulfate Sodium-Induced Colitis in Mice via Modulation of Intestinal Barrier Dysfunction and Microbiome Dysregulation.
    Luo L; Zhao Y; Zhang G; Dong S; Xu Y; Shi H; Zhang M; Liu X; Wang S; Luo H; Jing W
    J Pharmacol Exp Ther; 2024 Jun; 390(1):116-124. PubMed ID: 38816229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function.
    Yu S; Jiang J; Li Q; Liu X; Wang Z; Yang L; Ding L
    Front Cell Infect Microbiol; 2022; 12():855008. PubMed ID: 36132991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis.
    Liu X; Sun R; Li Z; Xiao R; Lv P; Sun X; Olson MA; Gong Y
    Arch Biochem Biophys; 2021 Oct; 711():109019. PubMed ID: 34478730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
    Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
    Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation.
    Chen L; Kan J; Zheng N; Li B; Hong Y; Yan J; Tao X; Wu G; Ma J; Zhu W; Sheng L; Chen L; Li B; Zhong J; Du J; Li H
    Phytomedicine; 2021 Oct; 91():153693. PubMed ID: 34403877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model.
    Sun R; Xu D; Wei Q; Zhang B; Aa J; Wang G; Xie Y
    Biomed Pharmacother; 2020 Mar; 123():109721. PubMed ID: 31865143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats.
    Zhang Y; Tang K; Deng Y; Chen R; Liang S; Xie H; He Y; Chen Y; Yang Q
    Biomed Pharmacother; 2018 Jun; 102():1025-1036. PubMed ID: 29710519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NF
    Ding X; Jian T; Li J; Lv H; Tong B; Li J; Meng X; Ren B; Chen J
    Oxid Med Cell Longev; 2020; 2020():9734560. PubMed ID: 33204402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.